Healthcare [ 5/11 ] | Biotechnology [ 54/112 ]
GB | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 31, 20 | -0.39 Decreased by -160.00% | -0.14 Decreased by -1.28 K% |
| Nov 4, 19 | -0.14 Increased by +73.58% | -0.12 Decreased by -138.89% |
| Aug 29, 19 | -0.25 Increased by +52.83% | -0.13 Decreased by -710.06% |
| May 29, 19 | -0.15 Decreased by -66.67% | -0.05 Decreased by -4.00 K% |
| Apr 23, 19 | -0.15 Increased by +85.00% | -0.05 Decreased by -4.00 K% |
| Sep 27, 18 | -0.53 Increased by +47.00% | -0.44 Decreased by -46.49% |
| Aug 17, 18 | -0.53 Decreased by -5.92 K% | -0.44 Decreased by -46.49% |
| Aug 16, 18 | -0.09 Decreased by -50.00% | -0.47 Increased by +172.02% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 22 | 0.00 Decreased by N/A% | -5.54 M Decreased by -26.70% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -5.11 M Increased by +12.50% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -5.61 M Increased by +17.72% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -1.43 M Decreased by -198.83% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -4.38 M Increased by +47.39% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 21 | 0.00 Decreased by N/A% | -5.84 M Decreased by -72.48% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 20 | 0.00 Decreased by N/A% | -6.82 M Increased by +13.41% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 20 | 0.00 Decreased by N/A% | 1.44 M Increased by +156.21% | Increased by +N/A% Decreased by N/A% |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.